Cybin seeks FDA approval for a new Phase 2 clinical trial aimed at treating “distress” among frontline healthcare practitioners.

UK-based Albert Labs receives conditional approval from the Canadian Securities Exchange (CSE) to commence trading under the symbol “ABRT”. Trading expected to commence in early 2022.

Seelos Therapeutics announces $20 million in new funding via convertible note, with an option for an additional $30 million.

Novamind announces unified branding of all subsidiaries and brands, and includes a new corporate logo.

The program aims to become one of the first hospital-based clinical sites to offer psychedelic medicine in the United States.

The 5th USPTO patent for Compass Pathways covers methods of treating depression with crystalline psilocybin.

St. Louis lawmakers on Tuesday unanimously approved a bill to decriminalize marijuana possession and cultivation for adults.

Digital therapeutics is the key to the rapid commercialization of psychedelic medicine. MINDCURE’s iSTRYM digital therapeutics platform is the first-mover in the industry.

In a new study, researchers show that one psychedelic, psilocybin, essentially repairs the part of the brain responsible for alcohol cravings, hinting at a potential new treatment for the disorder.

St. Louis lawmakers have given preliminary approval to a local measure to broadly decriminalize marijuana in the city.